Immediate Pathologic Effects on the Vein Wall of Foam Sclerotherapy

Orsini, Camillo; Brotto, Maurizio

doi:10.1111/j.1524-4725.2007.33261.x

Cited by 37 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One pathological study in vivo showed that a sclerosant in a foam vehicle completely destroyed the intimal barrier after 2-min exposure, leading to endothelial edema, exfoliation from the tunica media, and thrombogenesis in the tunica media over 30 min [14]. Polidocanol is a relatively weak sclerosant compared with conventional liquid sclerosants, such as ethanol or EO [15], but foam formulations have the same immediate pathological effect on the endothelium as liquid sclerosants.…”

Section: Discussionmentioning

confidence: 99%

Foam Sclerotherapy for a Symptomatic Hepatic Cyst: A Preliminary Report

Itou

Koizumi

Hashimoto

et al. 2013

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

PurposeWe evaluated our initial experience of performing sclerotherapy for symptomatic hepatic cysts using polidocanol foam instead of a liquid sclerosant.MethodsThree consecutively registered patients with symptomatic hepatic cysts (one with polycystic liver disease) underwent polidocanol foam sclerotherapy. A pigtail catheter was inserted into the targeted cyst following percutaneous cyst puncture under ultrasound guidance, and the cyst fluid was aspirated. To confirm the absence of communications between the cyst and surrounding hepatic vessels, 3 % polidocanol foam sclerosant was injected at a 1:4 ratio of polidocanol to air following digital subtraction cystography with carbon dioxide. C-arm computed tomography (CT) guidance also was used to monitor foam filling of the targeted cyst. The maximum dose of sclerosant injected per treatment session did not exceed 10 ml. The catheter was kept unclamped overnight for open drainage, and additional sclerotherapy sessions were performed on subsequent days, if needed.ResultsEfficient sclerotherapy was achieved with an average of two sessions. The initial mean cyst volume was 1,052 ml, and gradual resolution was observed without recurrence. The mean reduction rate was 97.9 % (97.7–98.3 %), and all cyst-associated symptoms disappeared. The median follow-up period was 17 (range 6–21) months. Although one patient experienced moderate-grade fever and another moderate pain at the puncture site, no major complications were observed.ConclusionPolidocanol foam sclerotherapy is a safe and effective treatment for symptomatic hepatic cysts.

show abstract

Section: Discussionmentioning

confidence: 99%

Foam Sclerotherapy for a Symptomatic Hepatic Cyst: A Preliminary Report

Itou

Koizumi

Hashimoto

et al. 2013

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

“…The mean number of punctures required per patient was 3.96 (3)(4)(5)(6)(7), the mean number of sessions was 1.4 (1-3) and the mean volume of foam per session was 8.5 mL (10-23 mL).…”

Section: Resultsmentioning

confidence: 99%

“…3 There are several studies of UGFS treatment for CVI reporting good clinical results and high rates of venous trunk occlusion assessed by vascular echography. 4,5 However, few publications have confirmed the clinical results obtained with UGFS using objective parameters, such as the hemodynamic variations provoked by the treatment.…”

mentioning

confidence: 99%

Evaluation of quality of life and photoplethysmography in patients with chronic venous insufficiency treated with foam sclerotherapy

Neto

Araújo²,

Kessler

2015

J. vasc. bras.

View full text Add to dashboard Cite

Background: Ultrasound-guided foam sclerotherapy plays a major role in treatment of chronic venous insufficiency, providing clinical and hemodynamic improvement to patients undergoing treatment. Objectives: To examine the relationships between venous refilling time and impact of venous disease on quality of life and between changes in venous refilling time and improvement of symptoms after ultrasound-guided foam sclerotherapy for chronic venous insufficiency. Methods: Thirty-two patients classified as C4, C5 or C6 answered a questionnaire on quality of life and symptoms and their venous filling time was measured using photoplethysmography before and 45 days after treatment of chronic venous insufficiency with ultrasound-guided foam sclerotherapy. Results: Statistically significant improvements were observed in quality of life scores and in venous filling time and in the following symptoms: aching, heavy legs, restless legs, swelling, burning sensations, and throbbing (p<0.0001). A similar improvement was also seen in the work and social domains of quality of life (p<0.0001). Conclusions: As confirmed by questionnaire scores and venous refilling times, ultrasound-guided foam sclerotherapy demonstrated efficacy and resulted in high satisfaction levels and low rates of major complications.

show abstract

“…Considering the good results of the ClariVein, our concept of mechanochemical ablation seems to be correct [5][6][7]. The mechanism of action of the Phlebogriffe has a solid pathophysiological basis [8][9][10]. The authors believe that the results of this pilot study will encourage further trials aimed at evaluation of this device.…”

Section: Discussionmentioning

confidence: 97%

Phlebogriffe – a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study

Ciostek¹,

Kowalski²,

Woźniak³

et al. 2015

View full text Add to dashboard Cite

Objectives: The aim of this study was to evaluate the feasibility, safety and early results of mechanochemical ablation of incompetent varicose veins using a special catheter: the Phlebogriffe. Material and methods:The design of this catheter is based on a typical diagnostic catheter. Into this catheter a metal shank, attached to which are 5 thin, curved, springy wires with sharpened ends, is introduced. After being pushed out of the catheter, these wires deploy into a cat's claw pattern. When the whole device -the catheter and shank with open claws -is being pulled out, sclerosing foam is administered. In this pilot study, which was performed in the years 2011-2013, we evaluated 40 patients with varicose veins. Efficacy of the procedure, defined as closure of the treated vein, and clinical result evaluated using the Venous Clinical Severity Score (VCSS) were assessed after 1, 3, 6 and 12 months. Results: Efficacy of the procedure after 1, 3, 6 and 12 months was 97.4%, 94.9%, 89.7% and 89.7%, respectively. Statistical analysis of the VCSS before the procedure and after 12 months revealed statistically significant improvements regarding pain, presence of varicose veins, oedema, number and size of active ulcers, their duration, size of active ulcers and the use of compression therapy. The average improvement in VCSS scores was 3.56 points. Conclusions:The Phlebogriffe is a device that offers new opportunities for safe and efficient treatment of varicose veins associated with incompetence of saphenous veins.

show abstract

Immediate Pathologic Effects on the Vein Wall of Foam Sclerotherapy

Abstract: In this in vivo report we analyze the capacity of 3% STD foam sclerotherapy to damage the saphenous vein wall. The damage is extremely fast and shows the detachment of the intimal and the development of the microthrombus.

Cited by 37 publications

References 9 publications

Foam Sclerotherapy for a Symptomatic Hepatic Cyst: A Preliminary Report

Foam Sclerotherapy for a Symptomatic Hepatic Cyst: A Preliminary Report

Evaluation of quality of life and photoplethysmography in patients with chronic venous insufficiency treated with foam sclerotherapy

Phlebogriffe – a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study

Contact Info

Product

Resources

About